Sector: Health Care | Focus: Life Sciences Tools & Services
HQ: Milford, Massachusetts
Financial Risks
The company faces risks from global economic and financial markets, currency fluctuations, customer demand fluctuations, competitor innovations, debt levels, operational disruptions, dependence on key personnel, intellectual property protection, supply chain disruptions, third-party sales, tax regulations, litigation, and accounting changes. The company's sales to academic and government customers are particularly vulnerable to funding cycles. The company also has unlimited potential liability under indemnification agreements.
Financial Upside
The company's sales increased 4% in Q3 2024 compared to Q3 2023. Strong customer demand, particularly in regions outside China, drove this growth. The company's service and consumable sales also saw growth. The Wyatt acquisition contributed to sales growth in Q3 2024 and the first nine months of 2024. The company has a large share repurchase program with $1 billion remaining authorization.
